Chemotherapy or Allogeneic Transplantation in High-Risk Philadelphia Chromosome-Negative Adult Lymphoblastic Leukemia.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Ribera JM
  • Morgades M
  • Ciudad J
  • Esteve J
  • Genesca E
  • Barba P
  • Ribera J
  • García Cadenas I
  • Moreno MJ
  • Martínez-Carballeira D
  • Torrent A
  • Martínez-Sánchez P
  • Monsalvo S
  • Gil C
  • Tormo M
  • Artola MT
  • Cervera M
  • González-Campos J
  • Rodríguez-Medina C
  • Bermúdez A
  • Novo A
  • Soria B
  • Coll R
  • Amigo ML
  • López A
  • Fernández Martín R
  • Serrano J
  • Mercadal S
  • Cladera A
  • Giménez-Conca AD
  • Peñarrubia MJ
  • Abella E
  • Vall-Llovera F
  • Hernández-Rivas JM
  • Garcia A
  • Bergua Burgues JM
  • de Rueda B
  • Sánchez-Sánchez MJ
  • Serrano A
  • Calbacho M
  • Alonso Vence N
  • Méndez-Sánchez JÁ
  • García-Boyero R
  • Olivares M
  • Barrena S
  • Zamora L
  • Granada I
  • Lhermitte L
  • Feliu E
  • Orfao A

Grupos

Abstract

The need for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adults with Philadelphia chromosome-negative (Ph-neg) acute lymphoblastic leukemia (ALL) with high-risk (HR) features and adequate measurable residual disease (MRD) clearance remains unclear. The aim of the ALL-HR-11 trial was to evaluate the outcomes of HR Ph-neg adult ALL patients following chemotherapy or allo-HSCT administered based on end-induction and consolidation MRD levels. Patients aged 15-60 years (y) with HR-ALL in complete response (CR) and MRD levels (centrally assessed by 8-color flow cytometry) <0.1% after induction and <0.01% after early consolidation, were assigned to receive delayed consolidation and maintenance therapy up to 2y in CR. The remaining patients were allocated to allo-HSCT. CR was attained in 315/348 patients (91%), with MRD <0.1% after induction in 220/289 patients (76%). By intention-to treat, 218 patients were assigned to chemotherapy and 106 to allo-HSCT. The 5-year (±95%CI) cumulative incidence of relapse (CIR), overall survival (OS) and event-free survival (EFS) probabilities for the whole series were 43%±7%, 49%±7% and 40±6%, respectively, with CIR and OS rates of 45±8% and 59±9% for patients assigned to chemotherapy and of 40±12% and 38±11% for those assigned to allo-HSCT, respectively. Our results show that avoiding allo-HSCT does not hamper the outcomes of HR Ph-neg adult ALL patients up to 60y with adequate MRD response after induction and consolidation. Better post-remission alternative therapies are especially needed for patients with poor MRD clearance. ClinicalTrials.gov (NCT01540812).

Datos de la publicación

ISSN/ISSNe:
0006-4971, 1528-0020

BLOOD  ELSEVIER

Tipo:
Article
Páginas:
1879-1894
PubMed:
33150388
Factor de Impacto:
5,515 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 75

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • MINIMAL RESIDUAL DISEASE; FLOW-CYTOMETRY; BLINATUMOMAB; THERAPY; MRD

Campos de Estudio

Cita

Compartir